Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride and dutasteride have little effect on Type 2 Diabetes risk.

This study found that individuals in this Egyptian cohort carrying the leucine (L) allele of the 5-α reductase type II enzyme had a higher risk of developing androgenetic alopecia, which may be associated with oxidative stress.

This study found that the methanolic heartwood extract of Avicennia marina significantly inhibits 5α-reductase type 1, reducing 5α-DHT production by 52% in a cell-based assay with human hair dermal papilla cells.

This review suggests that most mutations in the SRD5A2 gene show no clear genotype-phenotype correlation in 5-α-Reductase deficiency, although mutation location affects severity.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This study identified potent dual inhibitors of 5α-reductases 1 and 2 that may aid in designing new drugs for related diseases.

This study synthesized and evaluated hydroxycinnamate derivatives for their ability to inhibit human SRD5A1, finding that three compounds showed significant inhibitory activity and low cytotoxicity. Compound 10a notably reduced SRD5A1 protein expression in cells, suggesting potential for nonsteroidal treatment of androgen-related conditions.

This study reported that newly synthesized nonsteroidal compounds were effective at inhibiting prostatic 5 alpha reductase isozyme 2, especially the compound with an N, N-diisopropylcarbamoyl substituent, suggesting potential for treating benign prostatic hyperplasia.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.

This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

Saw palmetto extract can block the enzyme that converts testosterone in pig prostate cells.

In this study, treatment with a 5a-reductase inhibitor increased CD8+ T cell infiltration in benign prostatic hyperplasia tissues, suggesting an impact on inflammatory responses.

This study identified novel compounds as selective inhibitors of the type 1 isoenzyme of 5α-reductase, displaying promising potential for treating DHT-dependent disorders such as acne and androgenic alopecia.

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

This study found that octahydrobenzo[c]quinolizin-3-one derivatives, particularly compound 3, were potent and selective inhibitors of the enzyme 5α-reductase type 1.

In this study, researchers using QM/MM simulations identified key molecular motions and residue interactions in the enzyme SRD5A2 that significantly influence its catalytic efficiency, demonstrating that specific residues play critical roles in stabilizing transition states and reducing activation barriers.

In this study of Danioninae species, researchers reported that the presence of breeding tubercles on the pectoral fins is conserved in certain species and linked to local androgen conversion, with steroid 5-α-reductase playing a crucial role in their development.

This study found that novel compounds moderately inhibited 5α-reductase type 1 activity compared to finasteride, offering valuable data on structure-activity relationships.

This study reported that 5 alpha-reductase type 2 is the predominant enzyme in pubic skin fibroblasts across normal men, women, and hirsute patients, suggesting potential treatment options for idiopathic hirsutism.

This study investigates the potential of a cosmetic day lotion with a 5a-reductase inhibitor and a night lotion with an angiogenic ingredient to modulate hair growth, but reports no clinical results.

This study identified several herbs, including Ganoderma lucidum and Urtica dioica, that showed promising 5α-reductase inhibitory activity suggesting potential use in managing androgenic disorders.

This study suggests that the use of 5α-reductase inhibitors in men may be associated with macular abnormalities, characterized by cystoid changes and foveal cavitation, potentially progressing to more severe defects.

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

This study found that compounds 21–23 and 25 exhibited strong 5α-reductase II inhibition in vitro and significantly reduced rat prostate weight, performing comparably to finasteride.

This study isolated new geranylated coumarins from Mammea siamensis flowers and found that several of these compounds inhibit testosterone 5α-reductase.

Finasteride lowers PSA levels about the same whether taken at 1 mg or 5 mg daily.